Compare ADMA Biologics Inc (ADMA) vs Albemarle Corp. (ALB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Albemarle Corp. — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Albemarle Corp. trades at $130.66 (market cap $15.48B). The key difference: Albemarle Corp. is far larger — about 7.1× ADMA Biologics Inc's market cap, and Albemarle Corp. pays a 1.25% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ALB | |
|---|---|---|
Market Cap | $2.18B | $15.48B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $215.62 |
52-Week Low | $7.60 | $72.58 |
Enterprise Value | $2.25B | $17.96B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Albemarle (ALB) trades at $131.11, up 4.54% today, with a bullish technical signal and strong Q2 2026 earnings beating estimates. The stock shows improved cash flow and lithium demand strength, though valuation metrics like a P/E of 485.59 indicate high expectations. Recent news highlights earnings growth and dividend stability, with support at $127 and resistance at $134.
Outlook is cautiously optimistic with analyst consensus target of $184.50, but risks include volatile lithium prices and high valuation. Investment opportunity lies in sustained demand for energy storage, balanced by margin pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →
